medmix secures second consecutive CDP "A" Rating for Supplier Engagement. MWN-AI** Summary. medmix, a leading global provider of high-precision delivery devices, recently announced that it has achieved an "A" rating in the CDP's Supplier Engagement Assessment for the second consecutive year. This recognition places medmix among a select group of global leaders who are making significant strides in promoting climate action within their supply chains. The assessment, conducted by the CDP (formerly known as the Carbon Disclosure Project), evaluates how effectively companies manage climate-related risks across their supply chains, based on detailed disclosures submitted in their annual Climate Change Questionnaire. The scoring system ranges from A to D-, with A-rated companies distinguished as CDP Supplier Engagement Leaders, featured on a public leaderboard. medmix has demonstrated a strong commitment to collaborating with suppliers on emissions reduction targets, enhancing transparency, and promoting climate governance across its value chain. This proactive supplier engagement is critical, as the supply chain represents a significant portion of the company's overall emissions. René Willi, CEO of medmix, emphasized that achieving this rating for two consecutive years reflects the company's consistent approach to managing climate risk. It reinforces their commitment to maintaining high standards of transparency and accountability within their supply chain, assuring customers of their dedication to sustainability. Beyond the assessment, medmix's strategy for supplier engagement signifies a broader commitment to environmental and social responsibility. This initiative aligns with medmix's ambition to take a leadership role in sustainable supply chain management across its operations. As a company headquartered in Baar, Switzerland, and publicly traded on the SIX Swiss Exchange (SIX: MEDX), medmix continues to prioritize innovation and quality in delivering solutions across healthcare, consumer, and industrial markets. MWN-AI** Analysis. medmix has recently reinforced its position as a leader in sustainable business practices by securing an "A" rating from the CDP Supplier Engagement Assessment for the second consecutive year. This achievement highlights medmix's ongoing commitment to reducing climate-related risks in its supply chain, an area that significantly impacts the company's overall emissions profile. Investors should consider several factors when analyzing medmix's ongoing performance in the context of this award. First, the "A" rating not only demonstrates medmix's effective climate governance but also enhances its brand reputation, which can lead to increased customer loyalty and potential new customer acquisition in an increasingly eco-conscious marketplace. As corporate buyers focus on sustainability, medmix's practices could provide it with a competitive edge. Additionally, the company's effort to engage suppliers in emissions-reduction targets indicates a robust framework for managing sustainability-related risks. This proactive approach may mitigate supply chain disruptions and align medmix with global regulatory trends prioritizing environmental responsibility. Such alignment could subsequently drive future revenue growth and lower operational costs over time. However, investors should also remain aware of the broader market risks associated with the climate crisis. As pressures mount on corporations globally, companies that fall behind in sustainability efforts might face reputational risks or regulatory penalties. medmix has demonstrated resilience and forward-thinking by embedding sustainability within its core operations, providing a potentially advantageous position in the market. As such, it may be prudent for investors to consider increased exposure to medmix shares, particularly for those aligned with sustainable investment principles. Nevertheless, continuous monitoring of environmental policies and sector developments will be essential for assessing the company's long-term viability in the sustainable investment landscape. **MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release. September 15, 2026 03:06:00 am Baar, Switzerland-(Newsfile Corp. - September 15, 2026) - medmix has secured an "A" rating in CDP's Supplier Engagement Assessment for the second consecutive year, placing the company among a select group of global leaders recognized for driving climate action across their supply chains. CDP's Supplier Engagement Assessment evaluates how companies manage climate-related risk across their supply chains, based on disclosures in CDP's annual Climate Change Questionnaire. Scores range from A to D- across governance, target-setting, Scope 3 emissions reporting and supplier engagement, with A-rated companies recognized as CDP Supplier Engagement Leaders and named on CDP's public leaderboard. medmix remains committed to working with suppliers on emissions-reduction targets, transparency and climate governance across its value chain, which accounts for the largest share of the company's total emissions. This makes supplier engagement central to climate performance. "Achieving this rating for the second year in a row confirms that supplier engagement is a consistent part of how we manage climate risk," said René Willi, CEO of medmix. "It also shows our customers that we hold our supply chain to a high standard of transparency and accountability. We will keep working closely with our suppliers to build on this progress in the years ahead." medmix' approach to supplier engagement extends beyond this year's assessment. It reflects a broader commitment to environmental and social responsibility across the value chain, underpinning medmix' ambition to lead on sustainable supply chain management across its operations. About medmix medmix is a global leader in high-precision delivery devices, with leading positions in healthcare, consumer and industrial end-markets. Its customers benefit from its dedication to innovation and technological advancement that has resulted in over 900 active patents. Its 14 production sites worldwide together with its highly motivated and experienced team of nearly 2'700 employees are at service of its customers with uncompromising quality, proximity and agility. medmix is headquartered in Baar, Switzerland. Its shares are traded on the SIX Swiss Exchange (SIX: MEDX). www.medmix.swiss Inquiries: This document may contain forward-looking statements including, but not limited to, projections of financial developments, market activity, or future performance of products and solutions containing risks and uncertainties. These forward-looking statements are subject to change based on known or unknown risks and various other factors that could cause actual results or performance to differ materially. FAQ**. How does medmix plan to maintain its "A" rating in CDP's Supplier Engagement Assessment for future evaluations, and what specific measures are being taken to ensure continued supplier engagement and climate action? Medmix plans to maintain its "A" rating in CDP's Supplier Engagement Assessment by implementing robust supplier engagement programs, emphasizing climate action initiatives, and regularly monitoring and enhancing its sustainability practices to foster collaboration and accountability among suppliers. In what ways has medmix's commitment to environmental and social responsibility influenced its operational strategies, particularly in relation to its "Medmix MDMXF" brand and customer relations? Medmix's commitment to environmental and social responsibility has driven its operational strategies by integrating sustainable practices into the Medmix MDMXF brand, enhancing customer relations through transparency, eco-friendly product offerings, and community engagement initiatives. Given medmix's significant emissions from its supply chain, what metrics are being used to track and report Scope 3 emissions, and how will these impact its overall climate strategy moving forward? Medmix utilizes metrics such as supplier emissions data, life cycle assessments, and carbon intensity measurements to track Scope 3 emissions, which will be pivotal in shaping its climate strategy by prioritizing emission reductions across its supply chain and enhancing overall sustainability. How does medmix's achievement of being recognized on CDP's public leaderboard for consecutive years enhance its market position, particularly for the "Medmix MDMXF" brand in its targeted sectors? Medmix's recognition on CDP's public leaderboard for consecutive years bolsters its market position by demonstrating commitment to sustainability, enhancing brand trust and credibility, particularly for the "Medmix MDMXF" brand in sectors increasingly prioritizing environmentally responsible practices. **MWN-AI FAQ is based on asking OpenAI questions about Medmix (OTC: MDMXF).

medmix has launched FleXa, a customisable syringe platform for single-component dental materials. The Swiss company's new system offers manufacturers over 150 medical-grade colours, custom colour matching, and design options including custom shapes and foil printing. The platform features a patent-pending drip-reducing plunger design to minimise material waste, a 360° rotatable Grip Plate for improved ergonomics, and a silicone oil-free system. FleXa comes in four volumes: 0.75 mL, 1 mL, 2 mL, and 3 mL, with shared outer dimensions and compatible accessories. CEO René Willi said the platform helps dental manufacturers differentiate whilst simplifying their supply chain. The system is compatible with over 60 medmix Dispensing Tips and can be delivered preassembled or unassembled to suit different production setups.